NanoSurface Biomedical Acquires Silene Biotech

NanoSurface Biomedical Acquires Silene Biotech to Expand Stem Cell-based Technologies

25 September 2019
For Immediate Release

(Seattle, WA) - Seattle biotech company NanoSurface Biomedical, Inc., a leading provider of biomimetic cell-based assay platforms and services, announced today that it has acquired Silene Biotech, a Seattle biotechnology company focused on stem cell banking and services. This acquisition expands NanoSurface’s capabilities in developing human stem cell-based platforms and technologies to accelerate the development of new drugs. Under the agreement, NanoSurface has acquired Silene’s IP, cGMP laboratory facilities, and its research, development, and operations teams. NanoSurface will also continue to maintain Silene’s ongoing cell banking operations and Silene’s existing customer relationships.

“We at NanoSurface are excited to bring Silene Biotech and its team on board to join us in our mission of accelerating drug development with human-relevant stem cell-based assays and technologies. Silene’s experience with patient-specific stem-cell processes will be leveraged in our efforts of developing new assays to help bring safer and more effective medicines to market more quickly,” said Michael Cho, CEO of NanoSurface Biomedical.

Silene’s co-founder and former CEO, Dr. Alex Jiao, has joined NanoSurface as Director of Assay Development. Dr. Jiao stated, “Silene has always focused on developing personalized technologies using patient stem cells. This acquisition represents a synergistic combination of Silene’s stem cell processes and experience with NanoSurface’s innovative cell maturation technologies.”

Elliot Fisher, Chief Business Officer of NanoSurface Biomedical commented, “The integration of Silene’s team, facilities, and stem cell logistics experience into NanoSurface’s operations will enable new and broader applications for our combined customer base.”

 

About Silene Biotech: Founded by Alex Jiao and Lena Shaw, Silene is a 2017 Techstars Seattle Accelerator alumnus that provides consumer stem cell banking and services to enable access to future personalized therapies. Silene was recognized among the winners of the 2016 University of Washington Health Innovation Challenge.

About NanoSurface Biomedical, Inc.: NanoSurface Biomedical is a biotechnology company based in Seattle, WA that develops biomimetic technologies to enhance cell-based assays and accelerate drug development. NanoSurface was founded in 2015. www.nanosurfacebio.com

Silene Customer Inquiries
contact@silenebiotech.com

Media Contact
Heejoon Choi
Director of Marketing, NanoSurface Biomedical
heejoon@nanosurfacebio.com